跳至主要内容
临床试验/NCT02644395
NCT02644395已完成3 期

Thiazide Diuretics for Hypertension in Kidney Transplant Recipients Using Tacrolimus

Erasmus Medical Center1 个研究点 分布在 1 个国家目标入组 49 人开始时间: 2013年1月18日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
入组人数
49
试验地点
1
主要终点
Average daytime SBP

研究概览

简要总结

Background: Calcineurin inhibitors (CNIs) are the most commonly used immunosuppressive drugs to prevent rejection after kidney transplantation. However, the efficacy of preventing rejection comes at the cost of important side-effects. Among the most common side-effects is hypertension. Hypertension after kidney transplantation is clinically relevant, because it increases the risk of cardiovascular disease and is associated with increased graft loss and recipient mortality. The mechanism of CNI-induced hypertension is incompletely understood and, therefore, the treatment is currently empiric. These and other investigators recently showed that CNIs cause salt-sensitive hypertension by activating a sodium transporter in the kidney, namely the thiazide-sensitive sodium chloride cotransporter.

Hypothesis: The investigators hypothesize that thiazide diuretics are non-inferior to calcium channel blockers (CCBs) (currently usually the treatment of choice) for the treatment of CNI-induced hypertension.

Objective: To compare the blood pressure response to thiazide diuretics and CCBs in patients with CNI-induced hypertension.

Study design: Single-center, randomized cross-over trial.

Study population: Kidney transplant recipients with a good functioning allograft (eGFR > 30 ml/min) who are hypertensive (daytime systolic blood pressure > 140 mm Hg) and who do not have proteinuria (< 1 g/day).

Intervention: Patients will be randomized to receive chlorthalidone (12.5 mg once daily, if needed titrated to 25 mg once daily) or amlodipine (5 mg once daily, if needed titrated to 10 mg once daily).

Main study parameters/endpoints: 24-hour blood pressure recording.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Both drugs have long been registered for the treatment of hypertension. The side-effect profile of both drugs is considered to be equal. The burden of the study for the patients are blood pressure measurements using 30-minute automated blood pressure measurement and 24-hour ambulatory blood pressure measurement.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Kidney transplant recipients using tacrolimus
  • Average daytime SBP > 140 mm Hg (ABPM)
  • eGFR > 30 ml/min (MDRD)

排除标准

  • Use of glucocorticoids, co-trimoxazole, diuretics
  • Pregnancy
  • Serum sodium < 136, serum potassium < 3.5
  • Proteinuria > 1 g/day

研究组 & 干预措施

Amlodipine

Active Comparator

Current treatment of choice

干预措施: Amlodipine (Drug)

Chlorthalidone

Experimental

Testing new indication for approved drug

干预措施: Chlorthalidone (Drug)

结局指标

主要结局

Average daytime SBP

时间窗: 8 weeks

次要结局

  • Side effects(8 weeks)
  • Laboratory parameters(8 weeks)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Ewout Hoorn

Associate Professor

Erasmus Medical Center

研究点 (1)

Loading locations...

相似试验